Mirum Pharmaceuticals Inc Stock News

Mirum Pharma has three approved products and a promising pipeline, with volixibat showing superior interim data for PBC compared to competitors. It is a buy for volixibat's potential, which is 2-3 years away from approval, but supported in the interim by the other approved drugs. Financially, Mirum has a market cap of $2bn, a cash balance of $294mn, and a cash runway of over 12-15 quarters.

FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4).

FOSTER CITY, Calif.--(BUSINESS WIRE)-- #algs--Mirum Pharmaceuticals to Showcase Data from its LIVMARLI and Volixibat Clinical Programs at AASLD's The Liver Meeting.

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM ) Q3 2024 Earnings Conference Call November 12, 2024 8:30 AM ET Company Participants Andrew McKibben - Vice President, Investor Relations Chris Peetz - Chief Executive Officer Peter Radovich - President & Chief Operating Officer Joanne Quan - Chief Medical Officer Eric Bjerkholt - Chief Financial Officer Conference Call Participants Gavin Clark-Gartner -...

FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4).

FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences.

FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals to Announce Third Quarter 2024 Financial Results and Host Conference Call on November 12, 2024.

FOSTER CITY, Calif.--(BUSINESS WIRE)-- #alagillesyndrome--Mirum Pharmaceuticals to Showcase LIVMARLI Data from its ALGS and PFIC Programs at the NASPGHAN Annual Meeting .